Participants 29 66 5
in people at high cardiovascular risk
Participants 110 130 3
people with diabetes
Participants 365 561 7
4.5 yr in the HOPE (Heart Outcomes and Prevention Evaluation) study, which compared ramipril's effects to placebo in 9297 participants, including 3577 with diabetes and 1956 with microalbuminuria.
Participants 562 660 6
This report is restricted to 7674 participants with albuminuria data at baseline and at follow-up.
Participants 1745 1782 4
in nondiabetic and in diabetic people
